Patients with Parkinson disease tend to have an increase in iron content with reduced perfusion in the substantia nigra.
Up to half of patients with Parkinson disease are also diagnosed with dementia, but tools to track changes in cognition are lacking.
Patients with Parkinson disease have a higher prevalence of ophthalmologic symptoms than controls.
Stress-related disorders are associated with an increased risk for neurodegenerative diseases.
There is a distinct genetic signature for young-onset Parkinson disease even in cells from those who have no known Parkinson disease-related mutations.
A physically active lifestyle is associated with a reduced risk for Parkinson disease.
Olfactory dysfunction is a marker for a number of neuropsychiatric disorders, including Parkinson disease, Alzheimer disease, and schizophrenia.
In long-term care facilities, the rate of antipsychotic use in patients with PD ranges from 15% to 30%; however, the efficacy of AAPs in these patients has not been evaluated in large clinical trials.
Compared with standard care alone, outpatient palliative care is associated with benefits among patients with Parkinson disease and related disorders.
The FDA has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.